Novo Nordisk reported a significant expansion in its customer base for the Wegovy obesity treatment, with over 240,000 Americans starting the new oral Wegovy pill shortly after its launch in January 2026. The company recorded 3,071 retail pharmacy prescriptions for the oral Wegovy pill within the first four days of its launch, indicating rapid initial uptake. By mid-April 2026, prescriptions for the oral Wegovy pill surpassed two million, reflecting a sharp increase in its user base. Additionally, Novo Nordisk's sales of Wegovy in India rose 40% in April 2026, following substantial price cuts on starter doses. The company also achieved a key R&D milestone with FDA approval for a higher-dose version of Wegovy, which demonstrated an average weight loss of 20.7% over 72 weeks in clinical trials. Furthermore, Novo Nordisk's 2025 sales rose 6% to 309 billion Danish kroner, driven by growth in its obesity and diabetes care segments, despite warnings of potential sales declines in 2026 due to pricing pressures and competition.